Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.

ABSTRACT:

Background

In the phase 3 EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first-line platinum-based chemotherapy. We present a post hoc subgroup analysis of patients enrolled in Japan.

Methods

Patients were enrolled regardless of programmed cell death-ligand 1 status and randomized 1:1 to cemiplimab 350 mg intravenously every 3 weeks or investigator's choice  single-agent chemotherapy for up to 96 weeks. Primary endpoint was OS. Key secondary endpoints were progression-free survival (PFS) and objective response rate (ORR).

Results

Overall, 608 patients were randomized, of whom 56 (9.2%) were in Japan (cemiplimab, n = 2

SUBMITTER: Hasegawa K 

PROVIDER: S-EPMC11426160 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature